Clinical efficacy and prognosis of glucagon-like peptide-1 combined with metformin in the treatment of patients with type 2 diabetes

Objective To explore the clinical efficacy and prognosis of glucagon-like peptide-1 combined with metformin in the treatment of patients with type 2 diabetes.Methods A total of 70 patients with type 2 diabetes were selected and randomly divided into observation group and control group.The observation group was treated with metformin combined withliraglutide,and the control group was treated with metformin combined with sitagliptin.Theglycosylated hemoglobin (HbA1c),fasting blood glucose (FBG),two hours postprandial blood glucose (2hPBG),homeostasis model assessment-insulin resistance index (HOMA-IR),body mass index (BMI) and blood lipid levels were compared between the two groups.Incidence of complications was analyzed.Results After treatment,the HbA1c,FBG,2 hPBG,HOMA-IR,BMI and blood lipid levels in observation group were significantly better than those in control group (P ＜ 0.05).The incidence rate of adverse reactions was low in both groups.Conclusion glucagon-like peptide-1 combined with metformin is effective in the treatment of patients with type 2 diabetes.